Zelira Therapeutics Advances with HOPE® Trials
Company Announcements

Zelira Therapeutics Advances with HOPE® Trials

Zelira Therapeutics (AU:ZLD) has released an update.

Zelira Therapeutics has received the third tranche of funding, totaling US$681k, for its HOPE® 1 clinical trials from the 2011 Forman Trust, bringing the total SPV funding to US$2.569 million. The company has also secured significant patents for its HOPE® formulations in the treatment of Autism Spectrum Disorder and received a A$919k R&D Tax Incentive refund, which will be used to advance its clinical development programs. Additionally, Zelira is advancing the transformation of Zenivol® into a capsule form and preparing for FDA submissions, with a pre-IND meeting successfully held post-quarter.

For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics’ Financials: Borrowings Boost Cash Flow
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Advances in FDA Trials and Product Development
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Schedules Hybrid 2024 AGM
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App